Incyte Corp. INCY

NAS: INCY | ISIN: US45337C1027   25/04/2024
51,18 USD (-1,08%)
(-1,08%)   25/04/2024
Grafiek Incyte Corp. Grafiek Incyte Corp.
dinsdag 30 april 2024, 13:00
Kwartaalcijfers (1ste kwartaal)

Incyte Corp. in het nieuws

24 juli 2023 · Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease · Persbericht

7 maart 2023 · Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline · Persbericht

5 december 2022 · Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology · Persbericht

14 juni 2022 · FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata · Persbericht

20 mei 2022 · CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) · Persbericht

11 mei 2022 · FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 · Persbericht

26 maart 2022 · Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies · Persbericht

31 januari 2022 · Bedrijfsnieuws uit Amerika · Bolero.be

Net voor de beurs in de VS de deuren opent, blikken we even terug op het belangrijkste bedrijfsnieuws in Amerika. Elliott Management en Vista Equity Partners zouden Citrix Systems overnemen De Amerikaanse vermogensbeheerder...

28 januari 2022 · Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis · Persbericht

9 november 2021 · OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis · Persbericht

Profiel Incyte Corp.

Biotechnologie
Gezondheidstechnologie

Website: www.incyte.com

Hoofdzetel: Wilmington, Delaware vlag Verenigde Staten

CEO: Paul Friedman

Werknemers: 2.600

Aandelen Incyte Corp.

Beurswaarde: 11,62 miljard USD

Effecten: 224,53 miljoen

Winst per aandeel (12 maand):  PLUS

Koers-winstverhouding:  PLUS

Beta: 0,40

Mijn selecties